Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer
1998

Serum VEGF Levels in Ovarian Cancer

Sample size: 256 publication Evidence: low

Author Information

Author(s): A Obermair, C Tempfer, L Hefler, O Preyer, A Kaider, R Zeillinger, S Leodolter, C Kainz

Primary Institution: University Hospital of Vienna

Hypothesis

The study aims to determine the value of preoperative serum VEGF levels in the early diagnosis of ovarian cancer and in the differential diagnosis of adnexal masses.

Conclusion

VEGF does not appear to be a useful tool in the early diagnosis of ovarian cancer or for indicating the absence or presence of malignancy in patients with an adnexal mass.

Supporting Evidence

  • VEGF levels were significantly lower in healthy women compared to those with ovarian cancer.
  • At a threshold of 363.7 pg/ml, VEGF had a sensitivity of 54% and specificity of 77%.
  • CA 125 was found to be a more reliable marker for predicting malignancy than VEGF.

Takeaway

The study looked at a protein called VEGF in the blood of women to see if it could help find ovarian cancer early, but it turns out it doesn't really help.

Methodology

Preoperative serum VEGF levels were examined in healthy women, patients with benign ovarian cysts, and ovarian cancer patients using an ELISA.

Limitations

The study mainly included advanced-stage ovarian cancer patients, which may affect the generalizability of the results.

Participant Demographics

Mean age of participants was 47 years, with a range from 21 to 79 years.

Statistical Information

P-Value

0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication